Release Date: 17/06/22 09:14 Summary: Affirmation of FY22 guidance Price Sensitive: Yes Download Document 121.35KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%